EcoDrugPlus

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSACLG00000024918
Gene Symbol: LOC113037511
3 Cross references
241 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSACLG00000024326
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSACLG00000019668
Gene Symbol: CHRM3
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSACLG00000001933
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSACLG00000026585
Gene Symbol: CHRM5
3 Cross references
190 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSACLG00000015497
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSACLG00000018743
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSACLG00000015433
Gene Symbol: CHRNB4
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSACLG00000019090
Gene Symbol: CHRM2A
1 Cross references
196 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSACLG00000013765
Gene Symbol: CHRNA4B
1 Cross references
195 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACLG00000025951
Gene Symbol: F2R
4 Cross references
251 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACLG00000025911
Gene Symbol: F2R
4 Cross references
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).